Novo Nordisk shares fell 1.4% pre-market after the European Medicines Agency approved flexible shipping conditions for Wegovy. The injection can now be transported at up to 30 degrees for 48 hours, significantly easing supply chain constraints. This logistics boost reduces reliance on cold chain requirements, though the changes do not apply to the pill formulation pending regulatory approval.